Salusin-β in patients with subclinical hypothyroidism and low to moderate cardiovascular disease risk

Abstract

The study was approved by Zagazig Medical Institutional Review board (IRB#:6865) ABSTRACT Background and Objectives: Because Subclinical hypothyroidism may be a risk factor for cardiovascular disease, we aimed to measure the level of salusin-β which is a new biomarker for predicting atherosclerotic cardiovascular diseases (CVD) in those patients. Patients and Methods: 57 subclinical hypothyroid patients were compared with a control group of 60 euthyroid subjects whose age and sex were matched to the patient group. Both groups have low to moderate 10-year risk of fatal CVD. We studied the serum level of salusin-β in the selected group of SC hypothyroid patients to find out if it can be used as an indicator of the cardiovascular adverse effects in them. We also studied the association between salusin-β levels and thyroid stimulating hormone (TSH) level, thyroid Ab, and individual’s risk of CVD. Results: Salusin-β was higher in the SC hypothyroidism group with a significant difference (p = 0.001). TSH, FT4, diastolic BP and triglycerides showed a significant difference between the two groups. Systolic BP, total cholesterol, smoking, and SCORE showed no significant difference between the two groups. There was a highly +ve correlation with TSH level in the SC hypothyroid group. Conclusion:The elevated salusinβ level supports the opinion that SC hypothyroidism has a cardiovascular risk and can support treatment of these cases whose TSH < 10 mIU/l.